• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫颈癌进展过程中沉默调节蛋白(SIRT1、SIRT2和SIRT7)的表达/定位模式以及沉默调节蛋白抑制剂对宫颈癌细胞生长的影响。

Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells.

作者信息

Singh Sapna, Kumar P Uday, Thakur Suresh, Kiran Shashi, Sen Bijoya, Sharma Shreya, Rao Vishnu Vardhan, Poongothai A R, Ramakrishna Gayatri

机构信息

Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India.

出版信息

Tumour Biol. 2015 Aug;36(8):6159-71. doi: 10.1007/s13277-015-3300-y. Epub 2015 Mar 21.

DOI:10.1007/s13277-015-3300-y
PMID:25794641
Abstract

Sirtuins belong to the family of class III histone deacetylases; its role in neoplasia is controversial as both tumor-suppressive and promoting functions have been reported. There are very few reports available, where expressions of sirtuin isoforms are comprehensively analyzed during neoplasia. Therefore, in the present study, the expression of SIRT1, SIRT2, and SIRT7 during different stages of cervical cancer progression was analyzed. The normal cervical epithelium showed feeble expression of sirtuin isoforms, SIRT1, SIRT2, and SIRT7. A significant increase in SIRT1 expression was noted in the cytoplasm as well as in the nucleus of proliferative layers of cervical epithelium in squamous intraepithelial lesions (SIL); however, in the squamous cell carcinomas (SCC), a heterogeneous pattern of SIRT1 expression varying from low to high was noted. A progressive increase in the expression of both SIRT2 and SIRT7 was noted during cancer progression in the following order: normal < preneoplasia < cancer. Cervical cancer cell lines, HeLa and SiHa, showed higher levels of SIRT1 and SIRT2 in comparison to the immortalized cell counterpart, HaCaT. Specific inhibitors of SIRT1 (Ex527) and SIRT2 (AGK2) impaired the growth of the cervical cancer cells, SiHa, but not of the HaCaT cells. SIRT1 inhibition caused cell death, while SIRT2 inhibition resulted in cell cycle arrest. In conclusion, we report the overexpression of SIRT2 and SIRT7 proteins in cervical cancer and suggest probable application of sirtuin inhibitors as therapeutic targets. Further, a specific increase in the levels of SIRT1 in intraepithelial lesion makes it a promising candidate for identification of preneoplastic changes.

摘要

沉默调节蛋白属于Ⅲ类组蛋白去乙酰化酶家族;其在肿瘤形成中的作用存在争议,因为既有肿瘤抑制功能的报道,也有促进肿瘤功能的报道。关于在肿瘤形成过程中全面分析沉默调节蛋白亚型表达的报道非常少。因此,在本研究中,分析了宫颈癌进展不同阶段SIRT1、SIRT2和SIRT7的表达情况。正常宫颈上皮中沉默调节蛋白亚型SIRT1、SIRT2和SIRT7表达微弱。在鳞状上皮内病变(SIL)的宫颈上皮增殖层的细胞质和细胞核中,SIRT1表达显著增加;然而,在鳞状细胞癌(SCC)中,观察到SIRT1表达呈从低到高的异质性模式。在癌症进展过程中,SIRT2和SIRT7的表达按以下顺序逐渐增加:正常<瘤前病变<癌症。与永生化细胞HaCaT相比,宫颈癌细胞系HeLa和SiHa显示出更高水平的SIRT1和SIRT2。SIRT1(Ex527)和SIRT2(AGK2)的特异性抑制剂损害了宫颈癌细胞SiHa的生长,但不影响HaCaT细胞的生长。抑制SIRT1导致细胞死亡,而抑制SIRT2导致细胞周期停滞。总之,我们报道了SIRT2和SIRT7蛋白在宫颈癌中的过表达,并提出沉默调节蛋白抑制剂可能作为治疗靶点的应用。此外,上皮内病变中SIRT1水平的特异性增加使其成为识别瘤前病变的有希望的候选者。

相似文献

1
Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells.宫颈癌进展过程中沉默调节蛋白(SIRT1、SIRT2和SIRT7)的表达/定位模式以及沉默调节蛋白抑制剂对宫颈癌细胞生长的影响。
Tumour Biol. 2015 Aug;36(8):6159-71. doi: 10.1007/s13277-015-3300-y. Epub 2015 Mar 21.
2
Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS?肌萎缩侧索硬化症(ALS)尸检组织中差异表达的沉默调节蛋白:沉默调节蛋白在 ALS 中的神经保护或神经毒性特性?
Neurodegener Dis. 2013;11(3):141-52. doi: 10.1159/000338048. Epub 2012 Jul 10.
3
Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.沉默调节蛋白1和2的表达与非小细胞肺癌患者的不良预后相关。
PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.
4
Sirtuin inhibitors, EX527 and AGK2, suppress cell migration by inhibiting HSF1 protein stability.沉默调节蛋白抑制剂EX527和AGK2通过抑制热休克因子1(HSF1)蛋白的稳定性来抑制细胞迁移。
Oncol Rep. 2016 Jan;35(1):235-42. doi: 10.3892/or.2015.4381. Epub 2015 Nov 2.
5
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.沉默调节蛋白1和沉默调节蛋白2的抑制作用会损害小儿软组织肉瘤的生长。
Cell Death Dis. 2014 Oct 23;5(10):e1483. doi: 10.1038/cddis.2014.385.
6
High glucose-induced oxidative stress represses sirtuin deacetylase expression and increases histone acetylation leading to neural tube defects.高糖诱导的氧化应激会抑制沉默调节蛋白去乙酰化酶的表达,并增加组蛋白乙酰化,从而导致神经管缺陷。
J Neurochem. 2016 May;137(3):371-83. doi: 10.1111/jnc.13587. Epub 2016 Mar 17.
7
Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium.评估子宫内膜癌和非肿瘤性子宫内膜中沉默调节蛋白的表达。
Oncotarget. 2016 Jan 12;7(2):1144-54. doi: 10.18632/oncotarget.6691.
8
Resveratrol Induced Premature Senescence Is Associated with DNA Damage Mediated SIRT1 and SIRT2 Down-Regulation.白藜芦醇诱导的早衰与DNA损伤介导的SIRT1和SIRT2下调有关。
PLoS One. 2015 Apr 29;10(4):e0124837. doi: 10.1371/journal.pone.0124837. eCollection 2015.
9
Gene expression patterns of Sirtuin family members (SIRT1 TO SIRT7): Insights into pathogenesis and prognostic of Myelodysplastic neoplasm.Sirtuin 家族成员(SIRT1 至 SIRT7)的基因表达模式:对骨髓增生异常肿瘤发病机制和预后的深入了解。
Gene. 2024 Jul 15;915:148428. doi: 10.1016/j.gene.2024.148428. Epub 2024 Apr 3.
10
Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity.肥胖个体脂肪组织中沉默调节蛋白基因(SIRT1、SIRT2、SIRT3和SIRT6)及其靶基因水平的改变。
Diabetes Metab Syndr. 2019 Jan-Feb;13(1):582-589. doi: 10.1016/j.dsx.2018.11.011. Epub 2018 Nov 10.

引用本文的文献

1
SIRT7 regulates NUCKS1 chromatin binding to elicit metabolic and inflammatory gene expression in senescence and liver aging.SIRT7调节NUCKS1与染色质的结合,以引发衰老和肝脏衰老过程中的代谢和炎症基因表达。
Mol Cell. 2025 Jun 19;85(12):2390-2408.e6. doi: 10.1016/j.molcel.2025.05.025. Epub 2025 Jun 12.
2
SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer's disease.SIRT2和ALDH1A1作为阿尔茨海默病中星形胶质细胞产生γ-氨基丁酸的关键酶。
Mol Neurodegener. 2025 Jan 15;20(1):6. doi: 10.1186/s13024-024-00788-8.
3
Multifaceted regulation of sirtuin 2 (Sirt2) deacetylase activity.

本文引用的文献

1
Sirtuin 7 in cell proliferation, stress and disease: Rise of the Seventh Sirtuin!沉默调节蛋白7在细胞增殖、应激及疾病中的作用:第七个沉默调节蛋白的兴起!
Cell Signal. 2015 Mar;27(3):673-82. doi: 10.1016/j.cellsig.2014.11.026. Epub 2014 Nov 27.
2
Endoplasmic reticulum vacuolation and unfolded protein response leading to paraptosis like cell death in cyclosporine A treated cancer cervix cells is mediated by cyclophilin B inhibition.内质网空泡化和未折叠蛋白反应导致环孢素A处理的宫颈癌细胞发生类副凋亡样细胞死亡,这是由亲环蛋白B抑制介导的。
Biochim Biophys Acta. 2014 Nov;1843(11):2497-512. doi: 10.1016/j.bbamcr.2014.06.020. Epub 2014 Jul 5.
3
Sirtuin 2(Sirt2)去乙酰化酶活性的多方面调节。
J Biol Chem. 2024 Sep;300(9):107722. doi: 10.1016/j.jbc.2024.107722. Epub 2024 Aug 28.
4
The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy.组蛋白去乙酰化酶抑制剂在宫颈癌治疗中的新兴作用
Cancers (Basel). 2023 Apr 10;15(8):2222. doi: 10.3390/cancers15082222.
5
SIRT1 and gynecological malignancies (Review).SIRT1 与妇科恶性肿瘤(综述)。
Oncol Rep. 2021 Apr;45(4). doi: 10.3892/or.2021.7994. Epub 2021 Mar 2.
6
Sirtuin 2 in Endometrial Cancer: A Potential Regulator for Cell Proliferation, Apoptosis and RAS/ERK Pathway.Sirtuin 2 在子宫内膜癌中的作用:细胞增殖、凋亡和 RAS/ERK 通路的潜在调节剂。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980781. doi: 10.1177/1533033820980781.
7
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.癌症治疗中靶向组蛋白乙酰转移酶、组蛋白去乙酰化酶和溴结构域蛋白的小分子
Front Oncol. 2020 Nov 11;10:560487. doi: 10.3389/fonc.2020.560487. eCollection 2020.
8
Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD Dependent Lysine Deacetylases.沉默调节蛋白1抑制硫氰酸盐(S1th)——一类新型的NAD依赖型赖氨酸脱乙酰酶的同型选择性抑制剂。
Front Oncol. 2020 Apr 30;10:657. doi: 10.3389/fonc.2020.00657. eCollection 2020.
9
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.SIRT7:健康衰老和与年龄相关的髓系造血干细胞疾病发展的影响因素。
Leukemia. 2020 Aug;34(8):2206-2216. doi: 10.1038/s41375-020-0803-3. Epub 2020 Mar 25.
10
The sirtuin family in cancer.癌症中的 Sirtuin 家族。
Cell Cycle. 2019 Sep;18(18):2164-2196. doi: 10.1080/15384101.2019.1634953. Epub 2019 Jul 25.
SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
SIRT2:可手术乳腺癌中的肿瘤抑制因子还是肿瘤促进因子?
Eur J Cancer. 2014 Jan;50(2):290-301. doi: 10.1016/j.ejca.2013.10.005. Epub 2013 Oct 29.
4
Intracellular distribution of human SIRT7 and mapping of the nuclear/nucleolar localization signal.人源 SIRT7 的细胞内分布及核仁定位信号的作图。
FEBS J. 2013 Jul;280(14):3451-66. doi: 10.1111/febs.12346. Epub 2013 Jun 20.
5
SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein.SIRT1 通过下调 Bcl-2 蛋白抑制乳腺癌生长。
Oncol Rep. 2013 Jul;30(1):125-30. doi: 10.3892/or.2013.2470. Epub 2013 May 15.
6
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism.SIRT4 具有肿瘤抑制活性,并通过抑制线粒体谷氨酰胺代谢来调节细胞对 DNA 损伤的代谢反应。
Cancer Cell. 2013 Apr 15;23(4):450-63. doi: 10.1016/j.ccr.2013.02.024. Epub 2013 Apr 4.
7
Altered expression of SIRT gene family in head and neck squamous cell carcinoma.SIRT基因家族在头颈部鳞状细胞癌中的表达改变。
Tumour Biol. 2013 Jun;34(3):1847-54. doi: 10.1007/s13277-013-0726-y. Epub 2013 Mar 12.
8
SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling.SIRT2 在肝细胞癌中的过表达通过蛋白激酶 B/糖原合成激酶-3β/β-连环蛋白信号通路介导上皮间质转化。
Hepatology. 2013 Jun;57(6):2287-98. doi: 10.1002/hep.26278. Epub 2013 Apr 26.
9
Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.Sirtuin7 致癌潜能在人肝癌和它的章程由肿瘤遏抑 MiR-125a-5p 和 MiR-125b。
Hepatology. 2013 Mar;57(3):1055-67. doi: 10.1002/hep.26101. Epub 2013 Feb 11.
10
Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.Cortactin 与前列腺癌的肿瘤进展和预后不良有关,而 SIRT2 可能不是 HADC6 的促进剂,而是原位工作的促进剂。
J Clin Pathol. 2012 Dec;65(12):1088-96. doi: 10.1136/jclinpath-2012-200940. Epub 2012 Sep 3.